EpiVax, Inc

EpiVax uses immune-engineering to develop new vaccines and to improve the immunogenicity profiles of new drugs. The company is well known for its independent thinking and interdisciplinary scientists. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA...

Computational immunology,vaccine design,immunogenicity screening,engineering therapeutic proteins,deimmunization,cancer vaccines,immune engineering,biologics research and development,deimmunization,animal health vaccines,in silico prediction,and immunogenicity risk assessment

Epivax, inc operates in the Biotechnology research industry.

Epivax, inc's revenue is 11m - 100m

Epivax, inc has 11 - 50 employees.